8月10日，诺诚健华(09969.HK)盘中上涨5.17%，报15.04港元，成交额5838.7万港元。
消息面上，公司近期密集兑现临床里程碑：7月27日公告TYK2抑制剂ICP-488治疗中重度斑块状银屑病III期注册性试验达到主要终点；此前7月15日Soficitinib治疗中重度特应性皮炎III期同样达到主要终点，7月16日该药治疗白癜风II期亦达主要终点。多条自免管线集中读出积极数据，叠加公司A股上周累计上涨9.9%，港股延续补涨态势。同日生物科技板块整体走强，康方生物涨4.3%、荣昌生物涨4.7%、三生制药涨3.23%，行业情绪共振进一步推动个股上行。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.